Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection

Simple item page
dc.contributor.authorMederacke, Ingmar
dc.contributor.authorYurdaydın, Cihan
dc.contributor.authorGrosshennig, Anika
dc.contributor.authorErhardt, Andreas
dc.contributor.authorÇakaloğlu, Yılmaz
dc.contributor.authorYalçın, Kendal
dc.contributor.authorZeuzem, Stefan
dc.contributor.authorZachou, Kalliopi
dc.contributor.authorChatzikyrkou, Christos
dc.contributor.authorBozkaya, Hakan
dc.contributor.authorDalekos, George Nikolaos
dc.contributor.authorManns, Michael Peter
dc.contributor.authorWedemeyer, Heiner
dc.contributor.buuauthorGürel, Selim
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi.tr_TR
dc.contributor.scopusid7003706434tr_TR
dc.date.accessioned2022-03-31T11:00:04Z
dc.date.available2022-03-31T11:00:04Z
dc.date.issued2012-06
dc.description.abstractLong-term safety of treatment with hepatitis B virus (HBV) polymerase inhibitors is a concern. Adefovir dipivoxil (ADV) therapy has previously been associated with impairment of renal function. Limited data are available on the safety of combination therapy with nucleos(t)ide analogues and interferon alfa (IFNa). The aim of this analysis was to assess the renal function during combination therapy with peginterferon alfa-2a (PegIFNa-2a) plus ADV vs either drug alone in patients with hepatitis B/D co-infection. We performed a retrospective analysis of renal function data of patients treated in the Hep-Net/International Delta Hepatitis Intervention Trial 1(HIDIT-1-trial), a European multicenter study to investigate the efficacy of 48 weeks of therapy with PegIFNa-2a+ADV vs either drug alone in 90 patients with chronic hepatitis B/D co-infection. Glomerular filtration rates (GFR) were calculated by CockcroftGault (CG), abbreviated Modification of Diet in Renal Disease (MDRD) study and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. After 48 weeks of therapy GFR values were significantly lower in patients receiving adefovir-containing treatment vs PegIFNa-2a alone [mean difference 16.1 mL/min (CG) and 10.2 mL/min (MDRD), respectively, P < 0.05] while no differences were observed between patients receiving adefovir alone vs combination treatment. Twenty-four weeks after treatment GFR values did not differ between treatment arms. A decrease in GFR =20% was observed more often in patients during adefovir-containing treatment vs PegIFNa-2a alone (P < 0.05) which was confirmed by KaplanMeier analysis. Adefovir-containing but not PegIFNa-2a treatment was associated with a decrease in GFR values in about one-fifth of patients. Combination treatment of PegIFNa-2a+ADV in chronic hepatitis B/D co-infection did not lead to any further impairment of kidney function.en_US
dc.description.sponsorshipHep-Net Study Houseen_US
dc.description.sponsorshipFederal Ministry of Education & Research (BMBF)en_US
dc.description.sponsorshipHoffmann-La Rocheen_US
dc.description.sponsorshipGilead Sciencesen_US
dc.identifier.citationMederacke, I. vd. (2012). "Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection". Journal of Viral Hepatitis, 19(6), 387-395.en_US
dc.identifier.endpage395tr_TR
dc.identifier.issn1352-0504
dc.identifier.issn1365-2893
dc.identifier.issue6tr_TR
dc.identifier.pubmed22571900tr_TR
dc.identifier.scopus2-s2.0-84861101465tr_TR
dc.identifier.startpage387tr_TR
dc.identifier.urihttps://doi.org/10.1111/j.1365-2893.2011.01560.x
dc.identifier.urihttps://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01560.x
dc.identifier.urihttp://hdl.handle.net/11452/25493
dc.identifier.volume19tr_TR
dc.identifier.wos000303858900002tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.collaborationYurt dışıtr_TR
dc.relation.collaborationSanayitr_TR
dc.relation.journalJournal of Viral Hepatitisen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectGastroenterology & hepatologyen_US
dc.subjectInfectious diseasesen_US
dc.subjectVirologyen_US
dc.subjectAdefoviren_US
dc.subjectCombination therapyen_US
dc.subjectGlomerular filtration rateen_US
dc.subjectInterferonen_US
dc.subjectRenal functionen_US
dc.subjectSafetyen_US
dc.subjectGlomerular-filtration-rateen_US
dc.subjectDelta-virus-infectionen_US
dc.subjectSerum creatinineen_US
dc.subjectCombinationen_US
dc.subjectLamivudineen_US
dc.subjectPredictionen_US
dc.subjectManagementen_US
dc.subjectCirrhosisen_US
dc.subjectEquationen_US
dc.subjectTherapyen_US
dc.subject.emtreeAdefoviren_US
dc.subject.emtreePeginterferon alpha2aen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDelta agent hepatitisen_US
dc.subject.emtreeDrug efficacyen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGlomerulus filtration rateen_US
dc.subject.emtreeHepatitis ben_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeKidney functionen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeMixed infectionen_US
dc.subject.emtreeMonotherapyen_US
dc.subject.emtreeMulticenter studyen_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeRandomized controlled trialen_US
dc.subject.emtreeRetrospective studyen_US
dc.subject.meshAdenineen_US
dc.subject.meshAdolescenten_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshAleutian mink disease virusen_US
dc.subject.meshAntiviral agentsen_US
dc.subject.meshDrug therapy, combinationen_US
dc.subject.meshFemaleen_US
dc.subject.meshHepatitis ben_US
dc.subject.meshHepatitis den_US
dc.subject.meshHumansen_US
dc.subject.meshInterferon-alphaen_US
dc.subject.meshKidneyen_US
dc.subject.meshMaleen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshPhosphonic acidsen_US
dc.subject.meshPolyethylene glycolsen_US
dc.subject.meshRecombinant proteinsen_US
dc.subject.meshRetrospective studiesen_US
dc.subject.meshYoung adulten_US
dc.subject.scopusHepatitis B E Antigen; Entecavir; Telbivudineen_US
dc.subject.wosGastroenterology & hepatologyen_US
dc.subject.wosInfectious diseasesen_US
dc.subject.wosVirologyen_US
dc.titleRenal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infectionen_US
dc.typeArticle
dc.wos.quartileQ2en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus